Exclusive Summary

• - Only FDA-approved OTC epinephrine MDI (0.125 mg/actuation) with scarce global peers, enabling rapid entry into self-care retail channels.
• - No API patent barrier; reintroduced in the US in 2018, exclusivity has expired, and no FDA generics to date, creating a cross-border first-mover window.
• - ~262 million global asthma patients with widespread acute-relief needs; positioned for temporary relief of mild/intermittent symptoms, bridging access gaps.
• - FDA cGMP and US registration/commercialization provide strong quality and regulatory credentials for markets referencing FDA standards.
• - OTC status lowers total access cost and time versus prescriptions, and offers better portability and convenience versus nebulized OTC solutions.